Vitestro Introduces Aletta™: The First-Ever Autonomous Robotic Phlebotomy Device™ (ARPD™) 

Vitestro, a trailblazer in medical robotics, has officially unveiled the name of its autonomous blood-drawing device: Aletta™. As the first autonomous robotic system designed for venous blood collection, Aletta delivers precise and consistent results while redefining efficiency in phlebotomy. 

The name Aletta is a tribute to Dr. Aletta Jacobs, a Dutch physician whose contributions significantly influenced modern medicine. Dr. Jacobs, the first female doctor in the Netherlands, championed accessibility, medical innovation, and patient care. Inspired by her legacy, Aletta represents these same ideals, trust, empathy, innovation, and technological advancement, while reflecting Vitestro’s Dutch roots and its mission to transform phlebotomy worldwide.

“Aletta is more than a system with advanced technology; it is a trusted partner in patient care,” said Brian Joseph, Co-Founder and Commercial Director at Vitestro. “By giving the device a name, we reinforce its role in healthcare teams, fostering familiarity and trust among both medical professionals and patients. Aletta works in harmony with trained personnel, ensuring a seamless workflow while enhancing the accuracy, efficiency, and overall experience of blood collection.” 

Advancing Blood Collection with Robotic Precision 

As the first and only Autonomous Robotic Phlebotomy Device™ (ARPD™), Aletta establishes a new category in medical robotics dedicated to automating blood collection. By setting the global benchmark for precision, safety, and efficiency in venipuncture, Aletta allows phlebotomists and nurses to focus more on patient care while mitigating the impact of healthcare staffing shortages. 

Aletta integrates AI-driven Doppler ultrasound and imaging for precise vein identification, ensuring accurate and consistent blood draws with robotic-controlled needle insertion. The fully automated process minimizes variability and reduces reliance on human intervention while seamlessly fitting into hospital and laboratory workflows to optimize efficiency and patient throughput. Clinically validated in over 4,000 patients, Aletta has demonstrated safety and comfort, with pain levels comparable to or lower than manual blood draws. 

With CE certification secured and an initial commercial rollout underway in Europe, Vitestro is expanding the availability of Aletta across hospitals and laboratories. The company is also advancing toward U.S. regulatory approval, conducting a multi-center clinical trial in collaboration with top academic medical institutions and healthcare systems. As demand for automated blood collection solutions rises, Vitestro aims to establish ARPD technology as the global standard for diagnostic blood sampling, improving patient care while streamlining clinical operations. 

About Vitestro 

Vitestro is a global leader in medical robotics, headquartered in the Netherlands, with expertise spanning engineering, robotics, and commercialization in the U.S. and international markets. The company has pioneered the world’s first and only CE-marked Autonomous Robotic Phlebotomy Device™ (ARPD™), setting a new standard for venous blood collection. By integrating cutting-edge robotics, artificial intelligence, and imaging technology, Vitestro delivers enhanced precision, efficiency, and an improved patient experience. While Aletta has not yet received FDA approval, Vitestro is actively working toward U.S. regulatory clearance and continued global expansion.

Last chance to join MedTech Houston!

Time is running out to be part of MedTech Houston on March 13 at Levit Green – Conference Center, Floor 1, 6420 Levit Green Boulevard, Houston. Don’t miss this opportunity to connect with industry leaders, expand your network, and gain valuable insights into the latest trends, challenges, and breakthroughs shaping MedTech. Seats are filling fast—secure your spot today!